GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ATAI Life Sciences NV (NAS:ATAI) » Definitions » Change In Other Working Capital

ATAI Life Sciences NV (ATAI Life Sciences NV) Change In Other Working Capital : $-0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is ATAI Life Sciences NV Change In Other Working Capital?

ATAI Life Sciences NV's Change In Other Working Capital for the quarter that ended in Mar. 2024 was $-0.00 Mil. It means ATAI Life Sciences NV's Other Working Capital declined by $0.00 Mil from Dec. 2023 to Mar. 2024 .

ATAI Life Sciences NV's Change In Other Working Capital for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means ATAI Life Sciences NV's Other Working Capital stayed the same from Dec. 2022 to Dec. 2023 .

ATAI Life Sciences NV Change In Other Working Capital Historical Data

The historical data trend for ATAI Life Sciences NV's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ATAI Life Sciences NV Change In Other Working Capital Chart

ATAI Life Sciences NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Change In Other Working Capital
- - -5.96 - -

ATAI Life Sciences NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Other Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ATAI Life Sciences NV Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ATAI Life Sciences NV Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of ATAI Life Sciences NV's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

ATAI Life Sciences NV (ATAI Life Sciences NV) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ATAI Life Sciences NV (NAS:ATAI) » Definitions » Change In Other Working Capital
Comparable Companies
LCTX RENB AEON FATE ZURA IMRX HUMA ENTA SCPH CRMD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
ATAI:Mexico 9VC:Germany
Address
Wallstraße 16, Berlin, BB, DEU, 10179
Website
https://www.atai.life
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Executives
Florian Brand officer: See Remarks C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Anne Nagengast Johnson officer: Chief Accounting Officer C/O ATAI LIFE SCIENCES N.V., WALLSTRASSE 16, BERLIN 2M 10179
Apeiron Investment Group Ltd. 10 percent owner BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Sahil Kirpekar officer: Chief Business Officer C/O ATAI LIFE SCIENCES N.V., WALLSTRASSE 16, BERLIN 2M 10179
Stephen Bardin officer: Chief Financial Officer C/O ATAI LIFE SCIENCES N.V., KRAUSENSTRASSE 9-10, BERLIN 2M 10117
Gregory L Weaver officer: Chief Financial Officer 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107
Andrea Heslin Smiley director 600 LEE ROAD, SUITE 100, WAYNE PA 19087
Michael Auerbach director 158 HESTER STREET, APT 7F, NEW YORK NY 10013
Amir H Kalali director 4350 EXECUTIVE DRIVE SUITE 325, SAN DIEGO CA 92121
Christian Angermayer director, 10 percent owner BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Rosnay Alexis De director C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Srinivas Rao officer: See Remarks C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Sabrina Martucci Johnson director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Jason Camm director C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Presight Ii, Lp 10 percent owner C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014